Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
QLTI's Cash to Debt is ranked higher than
98% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. QLTI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
QLTI' s Cash to Debt Range Over the Past 10 Years
Min: 0.7  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
QLTI's Interest Coverage is ranked higher than
97% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. QLTI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
QLTI' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: 12.21
M-Score: -3.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -3.27
QLTI's ROE (%) is ranked higher than
72% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. QLTI: -3.27 )
Ranked among companies with meaningful ROE (%) only.
QLTI' s ROE (%) Range Over the Past 10 Years
Min: -45.67  Med: -6.58 Max: 51.71
Current: -3.27
-45.67
51.71
ROA (%) -3.16
QLTI's ROA (%) is ranked higher than
73% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. QLTI: -3.16 )
Ranked among companies with meaningful ROA (%) only.
QLTI' s ROA (%) Range Over the Past 10 Years
Min: -33.42  Med: -6.31 Max: 28.78
Current: -3.16
-33.42
28.78
ROC (Joel Greenblatt) (%) -290.85
QLTI's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. QLTI: -290.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
QLTI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -222.89  Med: -72.65 Max: 2.41
Current: -290.85
-222.89
2.41
EBITDA Growth (3Y)(%) -56.00
QLTI's EBITDA Growth (3Y)(%) is ranked lower than
94% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. QLTI: -56.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
QLTI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -56  Med: -0.75 Max: 85.3
Current: -56
-56
85.3
EPS Growth (3Y)(%) -47.70
QLTI's EPS Growth (3Y)(%) is ranked lower than
92% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. QLTI: -47.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
QLTI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.5  Med: -4.35 Max: 103.9
Current: -47.7
-66.5
103.9
» QLTI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

QLTI Guru Trades in Q4 2014

Jim Simons 218,687 sh (New)
First Eagle Investment 67,972 sh (New)
» More
Q1 2015

QLTI Guru Trades in Q1 2015

Jim Simons 341,324 sh (+56.08%)
First Eagle Investment 90,000 sh (+32.41%)
» More
Q2 2015

QLTI Guru Trades in Q2 2015

Charles Brandes 153,280 sh (New)
Jim Simons 564,415 sh (+65.36%)
First Eagle Investment Sold Out
» More
Q3 2015

QLTI Guru Trades in Q3 2015

Charles Brandes 181,840 sh (+18.63%)
Jim Simons 376,764 sh (-33.25%)
» More
» Details

Insider Trades

Latest Guru Trades with QLTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.97
QLTI's P/B is ranked higher than
89% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. QLTI: 0.97 )
Ranked among companies with meaningful P/B only.
QLTI' s P/B Range Over the Past 10 Years
Min: 0.27  Med: 1.12 Max: 2.49
Current: 0.97
0.27
2.49
POCF 50.57
QLTI's POCF is ranked lower than
73% of the 383 Companies
in the Global Biotechnology industry.

( Industry Median: 28.02 vs. QLTI: 50.57 )
Ranked among companies with meaningful POCF only.
QLTI' s POCF Range Over the Past 10 Years
Min: 1.84  Med: 8.84 Max: 23.83
Current: 50.57
1.84
23.83
EV-to-EBIT 2.08
QLTI's EV-to-EBIT is ranked higher than
80% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 20.72 vs. QLTI: 2.08 )
Ranked among companies with meaningful EV-to-EBIT only.
QLTI' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.9  Med: -7.30 Max: 17.4
Current: 2.08
-16.9
17.4
EV-to-EBITDA 2.69
QLTI's EV-to-EBITDA is ranked higher than
80% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 18.13 vs. QLTI: 2.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
QLTI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.6  Med: -8.30 Max: 10.1
Current: 2.69
-17.6
10.1
Current Ratio 30.53
QLTI's Current Ratio is ranked higher than
95% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. QLTI: 30.53 )
Ranked among companies with meaningful Current Ratio only.
QLTI' s Current Ratio Range Over the Past 10 Years
Min: 1.1  Med: 19.81 Max: 85.25
Current: 30.53
1.1
85.25
Quick Ratio 30.53
QLTI's Quick Ratio is ranked higher than
95% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. QLTI: 30.53 )
Ranked among companies with meaningful Quick Ratio only.
QLTI' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 19.37 Max: 85.25
Current: 30.53
1.07
85.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.00
QLTI's Price/Net Cash is ranked higher than
94% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. QLTI: 1.00 )
Ranked among companies with meaningful Price/Net Cash only.
QLTI' s Price/Net Cash Range Over the Past 10 Years
Min: 1  Med: 4.17 Max: 87
Current: 1
1
87
Price/Net Current Asset Value 0.99
QLTI's Price/Net Current Asset Value is ranked higher than
93% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 7.24 vs. QLTI: 0.99 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
QLTI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.48  Med: 3.24 Max: 30.62
Current: 0.99
0.48
30.62
Price/Tangible Book 0.97
QLTI's Price/Tangible Book is ranked higher than
92% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. QLTI: 0.97 )
Ranked among companies with meaningful Price/Tangible Book only.
QLTI' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.37  Med: 2.40 Max: 24.31
Current: 0.97
0.37
24.31
Price/Projected FCF 14.16
QLTI's Price/Projected FCF is ranked higher than
75% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 3.23 vs. QLTI: 14.16 )
Ranked among companies with meaningful Price/Projected FCF only.
QLTI' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.28  Med: 1.77 Max: 250
Current: 14.16
0.28
250
Earnings Yield (Greenblatt) (%) 48.10
QLTI's Earnings Yield (Greenblatt) (%) is ranked higher than
95% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. QLTI: 48.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
QLTI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5.8  Med: 44.40 Max: 882.9
Current: 48.1
5.8
882.9

More Statistics

Revenue(Mil) $43
EPS $ -0.07
Beta0.24
Short Percentage of Float0.64%
52-Week Range $2.33 - 4.50
Shares Outstanding(Mil)52.83

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil)
EPS($) -0.65 -0.54 -0.43
EPS without NRI($) -0.65 -0.54 -0.43

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:QLT.Canada, QLT.Germany,
QLT Inc was formed in 1981 under the laws of the Province of British Columbia. It is a biotechnology company conducts development and commercialization of ocular products that address the unmet medical needs of patients and clinicians. The Company is developing QLT091001, a synthetic retinoid compound for the potential treatment of certain age-related and inherited retinal degenerative diseases. Its competitors include pharmaceutical and biopharmaceutical companies. The research and development, preclinical studies and clinical trials, and ultimately, the manufacturing, marketing and labelling of its products, are subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and other countries.
» More Articles for QLTI

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: SWN, BECN, NSIT, HOLX, QLTI, THRX Aug 13 2012 
QLT Inc. Reports Operating Results (10-K) Mar 01 2011 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 3,000 Shares Nov 08 2010 
QLT Inc. Reports Operating Results (10-Q) Nov 03 2010 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 5,000 Shares Jun 23 2010 
QLT Inc. (QLTI) CFO Cameron Nelson buys 10,000 Shares Nov 10 2009 
QLT Inc. Reports Operating Results (10-Q) Nov 06 2009 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 10,000 Shares Nov 04 2009 
QLT Inc. Reports Operating Results (10-Q) Aug 06 2009 
100 Mile Diet Idea #1: QLT Inc -- a Cigar Butt with Legs? May 20 2009 

More From Other Websites
QLT INC/BC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Other Events,... Feb 05 2016
1:35 pm QLT Inc acquires 7.2 mln common shares in Aralez Pharmaceuticals, which was formed through... Feb 05 2016
QLT Announces Closing of Acquisition of Shares of Aralez Pharmaceuticals Inc. and Special... Feb 05 2016
QLT INC/BC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events,... Jan 13 2016
QLT Announces Results of Annual Meeting of Shareholders Jan 12 2016
QLT Announces Results of Annual Meeting of Shareholders Jan 12 2016
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 28 2015
QLT Calls Special Meeting of Its Shareholders in Connection With Aralez Pharmaceuticals Transaction Dec 28 2015
QLT Calls Special Meeting of Its Shareholders in Connection With Aralez Pharmaceuticals Transaction Dec 28 2015
The Road Ahead - Complementary Research on ReachLocal, ReneSola, Sky-mobi and QLT Dec 22 2015
QLT Commences Breach of Contract Action Against Valeant Pharmaceuticals Dec 16 2015
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 16 2015
QLT Commences Breach of Contract Action Against Valeant Pharmaceuticals Dec 16 2015
QLT INC/BC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Dec 11 2015
QLT INC/BC Financials Dec 08 2015
QLT, Deerfield and Other Leading Healthcare Investors Confirm Their Planned Investment in Aralez... Dec 07 2015
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 07 2015
QLT, Deerfield and Other Leading Healthcare Investors Confirm Their Planned Investment in Aralez... Dec 07 2015
Is QLT Inc. (QLTI) A Good Stock To Buy? Dec 03 2015
Is Basic Energy Services, Inc (BAS) Going to Burn These Hedge Funds? Dec 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK